AU2001231104A1 - Methods for treating diabetes - Google Patents

Methods for treating diabetes

Info

Publication number
AU2001231104A1
AU2001231104A1 AU2001231104A AU3110401A AU2001231104A1 AU 2001231104 A1 AU2001231104 A1 AU 2001231104A1 AU 2001231104 A AU2001231104 A AU 2001231104A AU 3110401 A AU3110401 A AU 3110401A AU 2001231104 A1 AU2001231104 A1 AU 2001231104A1
Authority
AU
Australia
Prior art keywords
methods
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231104A
Other languages
English (en)
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU2001231104A1 publication Critical patent/AU2001231104A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001231104A 2000-01-26 2001-01-24 Methods for treating diabetes Abandoned AU2001231104A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/491,420 US6337075B1 (en) 2000-01-11 2000-01-26 Methods for treating diabetes
US09491420 2000-01-26
PCT/US2001/002273 WO2001054711A2 (en) 2000-01-26 2001-01-24 Use of neurotoxins for treating diabetes

Publications (1)

Publication Number Publication Date
AU2001231104A1 true AU2001231104A1 (en) 2001-08-07

Family

ID=23952146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231104A Abandoned AU2001231104A1 (en) 2000-01-26 2001-01-24 Methods for treating diabetes

Country Status (11)

Country Link
US (2) US6337075B1 (enExample)
EP (1) EP1250146B1 (enExample)
JP (1) JP4851042B2 (enExample)
AR (1) AR029464A1 (enExample)
AT (1) ATE257013T1 (enExample)
AU (1) AU2001231104A1 (enExample)
DE (1) DE60101669T2 (enExample)
DK (1) DK1250146T3 (enExample)
ES (1) ES2211765T3 (enExample)
TW (1) TWI233806B (enExample)
WO (1) WO2001054711A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
ES2237551T3 (es) * 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6486127B1 (en) * 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
BRPI0510759A (pt) * 2004-05-07 2007-11-20 Phytotox Ltd método de facilitar a cura de um ferimento
EP1796676B1 (en) * 2004-05-07 2016-03-09 Phytotox Limited Transdermal administration of phycotoxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
WO2009002437A2 (en) * 2007-06-25 2008-12-31 The Board Of Regents Of The University Of Texas System Neurotoxin theraphy for postprandial hyperglycemia
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2972928B1 (fr) * 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2021231668A1 (en) 2020-05-15 2021-11-18 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
KR102520625B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
WO2021231666A1 (en) 2020-05-15 2021-11-18 Penland Foundation Treatment of asthma using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US12636343B2 (en) 2019-10-18 2026-05-26 Penland Foundation Treatment of vestibular vertigo using botulinum toxins
US20220143158A1 (en) * 2020-09-18 2022-05-12 Vanderbilt University Duodenal administration of botulinum toxin
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023287728A1 (en) * 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
DE69434535T2 (de) 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU6034396A (en) 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin

Also Published As

Publication number Publication date
DK1250146T3 (da) 2004-04-26
WO2001054711A3 (en) 2002-02-21
US6416765B1 (en) 2002-07-09
EP1250146A2 (en) 2002-10-23
TWI233806B (en) 2005-06-11
US20020031529A1 (en) 2002-03-14
JP4851042B2 (ja) 2012-01-11
DE60101669D1 (de) 2004-02-05
AR029464A1 (es) 2003-07-02
DE60101669T2 (de) 2004-10-21
ES2211765T3 (es) 2004-07-16
US6337075B1 (en) 2002-01-08
JP2003520822A (ja) 2003-07-08
EP1250146B1 (en) 2004-01-02
ATE257013T1 (de) 2004-01-15
WO2001054711A2 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2002215125A1 (en) Well treatment method
WO2002030487A8 (en) Methods for treating aneurysms
AU2002223827A1 (en) Well treatment
AU2001227966A1 (en) Methods for treating tumors
AU6908500A (en) Treatment for narcolepsy
AU2001241903A1 (en) Snow-gliding apparatus
AU2001238369A1 (en) Method for treating thyroid disorders
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU2002210881A1 (en) Transdermal method
AU2002336405A1 (en) Methods for treating deodorizer distillate
AU2001237939A1 (en) Methods for treating glaucoma
AU2001273609A1 (en) Process for treating wood
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001291313A1 (en) Process for making 3-amino-2-chloro-4-methylpyridine
AU2002214487A1 (en) Method for inducing apoptiosis
AU2002218440A1 (en) New process
AU5650401A (en) Method for enhancing cognitive function
AU2001237530A1 (en) Method
AU2001295036A1 (en) Apparatus for performing microcurrentelectrotherapy
AU2002210497A1 (en) Dimming apparatus
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2001243297A1 (en) Method for treating or preventing depression
AU2001241636A1 (en) Halotherapy method
AU2001267769A1 (en) Process
AU2002220757A1 (en) Method for obtaining azaerythromycin